Weight loss & metabolic health
Retatrutide
A triple agonist (GIP, GLP-1 and glucagon receptors) in phase 3 trials for obesity. Not approved yet.
How it works
It activates three hormone receptors at once: GLP-1 and GIP, which cut appetite and improve insulin, and glucagon, which raises energy use and fat burning in the liver.
What it is used for
Obesity. Also studied for type 2 diabetes, fatty liver and knee osteoarthritis.
What the evidence says
In a phase 2 trial, the highest dose led to about 24% weight loss in 48 weeks. Phase 3 trials are running and it is not approved yet.
Side effects and cautions
Nausea, vomiting, diarrhea and constipation, more at higher doses, plus a higher heart rate. Anything sold outside clinical trials is unregulated.
Half-life
About 6 days (clinical studies)
Makes sense for
- Adults with obesity, mainly within clinical trials
Does not make sense for
- A history of pancreatitis or gallbladder disease
- Medullary thyroid cancer or MEN2
- People at a healthy weight
Boost the effect
- High-protein meals (about 1.2–1.6 g per kg of body weight a day): help keep muscle while you lose weight
- Strength training 2–3 times a week: protects muscle and strength
- Plenty of water and fiber: ease the usual constipation and nausea